Skip to content
Trial Eligibility
Menu

A Study to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or Overweight (VESPER-SUI)

NCT07932925

This study is recruiting at 6 US sites in 4 states, according to its ClinicalTrials.gov record last updated .

Summary

The purpose of this study is to learn about the safety and effectiveness of berobenatide in adult women who have both stress urinary incontinence (SUI) and obesity or overweight. Participants will be in the study for about 63 weeks

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Urinary Incontinence, Stress
  • Overweight and/or Obesity

Eligibility basics and study details

Study type
Interventional
Phase
Phase 3
Ages
18 years and older
Sex
Female
Healthy volunteers
Not accepted
Sponsor
Pfizer
Last updated on ClinicalTrials.gov
November 19, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

California · 2

  • Madison Imaging Center · Citrus Heights, CA
  • Northern California Research · Sacramento, CA

Florida · 2

  • Hawthorne Health - Boynton Beach, FL · Boynton Beach, FL
  • New Age Medical Research Corporation · Miami, FL

Pennsylvania · 1

  • Hawthorne Health - Horsham, PA · Horsham, PA

Texas · 1

  • Clinical Trial Network · Houston, TX

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.